Table 2. Validated colorectal cancer associated serum N-glycan alterations.
N-Glycans | Discovery set | Validation sets | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cases vs. controls | Cases vs. controls | Cases vs. post-operative cases | |||||||||
Composition | Structure* | m/z [M+Na]+ | Alteration in CRC | Fold Change Case vs Control | VIP | p-valuea | Z-scoreb | p-valuea | Z-score | p-valuec | Z-score |
H4N4F1 | 1647.59 | down | 0.73 | 1.5 | 4.00E−08 | −5.5 | 1.00E−03 | −3.3 | 1.00E−03 | −3.2 | |
H5N4 | 1663.58 | down | 0.72 | 1.6 | 2.80E−08 | −5.6 | 4.00E−04 | −3.5 | 7.00E−03 | −2.7 | |
H5N4F1 | 1809.64 | down | 0.59 | 2.0 | 3.50E−15 | −7.9 | 2.20E−05 | −4.2 | 4.00E−03 | −2.9 | |
H4N4E1 | 1820.66 | down | 0.81 | 1.4 | 2.80E−06 | −4.7 | 4.00E−03 | −2.9 | 5.70E−02 | −1.9 | |
H4N5F1 | 1850.67 | down | 0.81 | 1.2 | 4.40E−07 | −5.1 | 1.20E−05 | −4.4 | 1.50E−04 | −3.8 | |
H5N5F1 | 2012.72 | down | 0.80 | 1.3 | 1.50E−07 | −5.3 | 4.80E−04 | −3.5 | 2.00E−04 | −3.7 | |
H5N4F1L1 | 2082.72 | down | 0.81 | 2.1 | 1.60E−09 | −6 | 5.00E−05 | −4.1 | 1.10E−05 | −4.4 | |
H5N4F1E1 | 2128.77 | down | 0.77 | 1.9 | 9.30E−13 | −7.1 | 1.00E−03 | −3.2 | 1.00E−03 | −3.4 | |
H5N4F1L2 | 2355.81 | down | 0.89 | 1.6 | 2.40E−04 | −3.7 | 3.00E−03 | −2.9 | 7.80E−02 | −1.8 | |
H6N5F1E1L1 | 2766.98 | up | 1.23 | 1.1 | 2.90E−04 | −3.6 | 2.00E−04 | −3.7 | 4.50E−06 | −4.6 | |
H6N5E3 | 2986.09 | up | 1.27 | 1.4 | 2.90E−06 | −4.7 | 2.00E−03 | −3.1 | 1.00E−04 | −3.9 | |
H6N5F1E1L2 | 3040.07 | up | 1.31 | 1.3 | 1.70E−05 | −4.3 | 7.30E−05 | −4 | 8.90E−06 | −4.4 | |
H6N5F1E2L1 | 3086.11 | up | 1.48 | 1.4 | 4.40E−07 | −5 | 7.00E−05 | −4 | 2.50E−07 | −5.2 | |
H6N5F1E3 | 3132.15 | up | 1.37 | 1.5 | 1.90E−06 | −4.8 | 2.00E−04 | −3.7 | 4.90E−05 | −4.1 | |
H6N5F2E1L2 | 3186.13 | up | 1.39 | 1.2 | 1.30E−04 | −3.8 | 2.20E−04 | −3.7 | 2.20E−06 | −4.7 | |
H6N5F2E2L1 | 3232.17 | up | 1.38 | 1.3 | 2.10E−05 | −4.3 | 1.20E−04 | −3.8 | 4.7E−05 | −4.1 | |
H7N6F1E1L2 | 3405.20 | up | 1.29 | 1.2 | 5.00E−05 | −4.1 | 3.00E−05 | −4.2 | 8.70E−05 | −3.9 | |
H9N8E1 | 3443.24 | up | 1.27 | 1.2 | 1.00E−03 | −3.4 | 3.50E−04 | −3.6 | 3.10E−05 | −4.2 | |
H7N6F1E2L1 | 3451.24 | up | 1.29 | 1.4 | 1.00E−03 | −3.4 | 7.50E−05 | −4 | 1.40E−04 | −3.8 | |
H7N6F1E2L2 | 3724.33 | up | 1.43 | 1.4 | 3.20E−06 | −4.7 | 1.30E−05 | −4.4 | 3.60E−05 | −4.1 |
*structural isomers cannot be excluded
aMann-Whitney U test, p-value < 0.01
bZ-score: indicates how many standard deviations an element is from the mean
cWilcoxon signed ranks test, p-value < 0.1; m/z, mass to charge ratio; M, mass; Na, sodium; VIP, variable importance in projection; CRC, colorectal cancer; H, hexose; N, N-acetylhexosamine; F, fucose; E, α2,6-linked sialic acid; L, α2,3-linked sialic acid.